Pharmacologic Substance
Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales
Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor
Pfizer Boosts Revenue Forecast by $1.5 Billion Amid Paxlovid Rebound, Despite Criticism from Starboard
Pfizer, revenue outlook, Paxlovid, Starboard, pharmaceuticals, COVID-19, financial performance
Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing
Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals
Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling
Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial
FDA Approves Protega’s 10 mg Abuse-Deterrent Opioid Roxybond for Pain Management
FDA approval, Protega Pharmaceuticals, Roxybond, abuse-deterrent opioid, pain management, SentryBond technology
Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance
Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Ottimo Pharma Emerges with David Epstein at Helm, Focusing on Novel PD1/VEGFR2 Bi-Functional Antibody
Ottimo Pharma, David Epstein, PD1/VEGFR2 bi-functional antibody, Cancer immunotherapy, VEGF bifunctional antibody, Biotech startup
FDA Approves Iterum’s Orlynvah for Uncomplicated UTIs, Offering New Hope for Patients with Limited Treatment Options
Iterum Therapeutics, Orlynvah, FDA approval, uncomplicated urinary tract infections (uUTIs), oral antibiotic, sulopenem, antimicrobial resistance
GSK’s Arexvy RSV Vaccine Shows Promise in Younger Adults, Following Pfizer’s Approval
GSK, Arexvy, RSV vaccine, younger adults, Pfizer, ABRYSVO, respiratory syncytial virus, lower respiratory tract disease